- Home
- JVA vs SNTI Comparison
JVA vs SNTI Comparison
Compare JVA & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JVA
- SNTI
- Stock Information
- Founded
- JVA 1971
- SNTI 2016
- Country
- JVA United States
- SNTI United States
- Employees
- JVA N/A
- SNTI N/A
- Industry
- JVA Packaged Foods
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- JVA Consumer Staples
- SNTI Health Care
- Exchange
- JVA Nasdaq
- SNTI Nasdaq
- Market Cap
- JVA 14.7M
- SNTI 14.1M
- IPO Year
- JVA 2005
- SNTI N/A
- Fundamental
- Price
- JVA $2.98
- SNTI $2.21
- Analyst Decision
- JVA
- SNTI
- Analyst Count
- JVA 0
- SNTI 0
- Target Price
- JVA N/A
- SNTI N/A
- AVG Volume (30 Days)
- JVA 181.9K
- SNTI 20.4K
- Earning Date
- JVA 10-18-2024
- SNTI 11-11-2024
- Dividend Yield
- JVA N/A
- SNTI N/A
- EPS Growth
- JVA N/A
- SNTI N/A
- EPS
- JVA 0.20
- SNTI N/A
- Revenue
- JVA $76,111,698.00
- SNTI $338,000.00
- Revenue This Year
- JVA N/A
- SNTI $254.47
- Revenue Next Year
- JVA N/A
- SNTI $169.66
- P/E Ratio
- JVA $13.96
- SNTI N/A
- Revenue Growth
- JVA 17.27
- SNTI N/A
- 52 Week Low
- JVA $0.67
- SNTI $1.52
- 52 Week High
- JVA $3.88
- SNTI $8.48
- Technical
- Relative Strength Index (RSI)
- JVA 53.73
- SNTI 38.51
- Support Level
- JVA $2.69
- SNTI $2.05
- Resistance Level
- JVA $3.12
- SNTI $2.48
- Average True Range (ATR)
- JVA 0.26
- SNTI 0.25
- MACD
- JVA -0.07
- SNTI -0.05
- Stochastic Oscillator
- JVA 27.62
- SNTI 12.90
About JVA Coffee Holding Co. Inc.
Coffee Holding Co Inc is engaged in the business of wholesale coffee operations, including manufacturing, roasting, packaging, marketing and distributing roasted and blended coffees for private labeled accounts and its own brands, and it sells green coffee. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada and certain countries in Asia.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.